Everything below concerns dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-24. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
=== Gastrointestinal === Diarrhoea that is characteristic of coeliac disease is chronic, sometimes pale, of large volume, and abnormally foul in odour. Other symptoms of coeliac disease include abdominal pain, cramping, bloating with abdominal distension, and mouth ulcers. As the bowels become more damaged, lactose intolerance can develop.
=== Vaccine skepticism and connection to autism === In 2009, Carrey wrote an article questioning the merits of vaccination and discussing its connection to autism for The Huffington Post. With former partner Jenny McCarthy, Carrey led a "Green Our Vaccines" march in Washington, D.C., to advocate for the removal of "toxic substances" from children's vaccines, out of a belief that children had received "too many vaccines, too soon, many of which are toxic". The rally was criticized by David Gorski, an American surgical oncologist on Science-Based Medicine blog, for being anti-vaccine and not "pro-safe vaccine", and by Steven Parker on the WebMD website for being "irresponsible". In 2009, the couple appeared on Larry King Live to discuss autism. Carrey stated that he believes autism "is preventable and treatable," and that "it's still shocking to see how many people are ignoring this information." Carrey suggested rising autism rates was a warning about the medical industry, stating: "There's an autistic child on every block ... Autism is the canary in the coal mine. I believe that it's telling us that this vaccine program is imbalanced." On July 1, 2015, after the signing of a new vaccination law, Carrey called California governor Jerry Brown a "corporate fascist" who was "poisoning" children by enacting the vaccination requirements. The law disallowed religious and philosophical reasons for exemption from vaccination.
== Bibliography == Wergedahl, H; Liaset, B; Gudbrandsen, OA; Lied, E; Espe, M; Muna, Z; Mørk, S; Berge, RK (2004). "Fish protein hydrolysate reduces plasma total cholesterol, increases the proportion of HDL cholesterol, and lowers acyl-CoA:cholesterol acyltransferase activity in liver of Zucker rats". The Journal of Nutrition. 134 (6): 1320–7. doi:10.1093/jn/134.6.1320. PMID 15173391. Wu, Hui-Chun; Chen, Hua-Ming; Shiau, Chyuan-Yuan (2003). "Free amino acids and peptides as related to antioxidant properties in protein hydrolysates of mackerel (Scomber austriasicus)". Food Research International. 36 (9–10): 949–957. doi:10.1016/S0963-9969(03)00104-2. INIST 15251156. Marchbank, T.; Limdi, J. K.; Mahmood, A.; Elia, G.; Playford, R. J. (2008). "Clinical trial: Protective effect of a commercial fish protein hydrolysate against indomethacin (NSAID)-induced small intestinal injury". Alimentary Pharmacology & Therapeutics. 28 (6): 799–804. doi:10.1111/j.1365-2036.2008.03783.x. PMID 19145735. S2CID 31397. Nesse, Knut Olav; Nagalakshmi, A. P.; Marimuthu, P.; Singh, Mamta (2011). "Efficacy of a Fish Protein Hydrolysate in Malnourished Children". Indian Journal of Clinical Biochemistry. 26 (4): 360–5. doi:10.1007/s12291-011-0145-z. PMC 3210250. PMID 23024471. Kristinsson, Hordur G.; Rasco, Barbara A. (2000). "Fish Protein Hydrolysates: Production, Biochemical, and Functional Properties". Critical Reviews in Food Science and Nutrition. 40 (1): 43–81. doi:10.1080/10408690091189266. PMID 10674201. S2CID 28085824. Webb, K. E.; Bergman, E. N. (1991).
isomerase Any of a class of enzymes which catalyze the conversion of a molecule from one isomer to another, such that the product of the reaction has the same molecular formula as the original substrate but differs in the connectivity or spatial arrangement of its atoms.
Sources: en.wikipedia.org
=== United Kingdom === The following programs of study have currently been approved by the General Dental Council for the profession of clinical dental technologist. Required prerequisites must be completed prior to enter Clinical Dental Technology Program. On successful completion of the selected courses, individuals are required to register with the General Dental Council to practice legally as a clinical dental technologist.
== Bibliography == Szilágyi, Miklós (1988). Electron and ion optics. New York: Plenum Press. ISBN 978-0-306-42717-6. Septier, Albert L. (1980). Applied charged particle optics. Boston: Academic Press. ISBN 978-0-12-014574-4. International vocabulary of basic and general terms in metrology =: Vocabulaire international des termes fondamentaux et généraux de métrologie. International Organization for Standardization. 1993. ISBN 978-92-67-01075-5. IUPAP Red Book SUNAMCO 87-1 "Symbols, Units, Nomenclature and Fundamental Constants in Physics" (does not have an online version) Symbols Units and Nomenclature in Physics IUPAP-25, E.R. Cohen & P. Giacomo, Physics 146A (1987) 1–68
=== ENOUGH === Funded by: Horizon 2020 (European Commission) and European Green Deal Duration: 4 years (October 2021-September 2025) Objective: The main scope of the project is to support the EU farm-to-fork sustainable strategy by providing technical, financial, and political tools and solutions to reduce GHG emissions (by 2030) and achieve carbon neutrality (by 2050) in the food industry.
Civilization has historically flourished around rivers and major waterways; Mesopotamia, one of the so-called cradles of civilization, was situated between the major rivers Tigris and Euphrates; the ancient society of the Egyptians depended entirely upon the Nile. The early Indus Valley civilization (c. 3300 BCE – c. 1300 BCE) developed along the Indus River and tributaries that flowed out of the Himalayas. Rome was also founded on the banks of the Italian river Tiber. Large metropolises like Rotterdam, London, Montreal, Paris, New York City, Buenos Aires, Shanghai, Tokyo, Chicago, and Hong Kong owe their success in part to their easy accessibility via water and the resultant expansion of trade. Islands with safe water ports, like Singapore, have flourished for the same reason. In places such as North Africa and the Middle East, where water is more scarce, access to clean drinking water was and is a major factor in human development.
Much of the attention on production of proinflammatory cytokines has focused on the IKK-beta/NF-kappa-B pathway, a protein network that enhances transcription of inflammatory markers and mediators that may cause insulin resistance. Second, visceral adiposity is related to an accumulation of fat in the liver, a condition known as non-alcoholic fatty liver disease (NAFLD). The result of NAFLD is an excessive release of free fatty acids into the bloodstream (due to increased lipolysis), and an increase in hepatic breakdown of glycogen stores into glucose (glycogenolysis), both of which have the effect of exacerbating peripheral insulin resistance and increasing the likelihood of Type 2 diabetes mellitus. The excessive expansion of adipose tissue that tends to occur under a sustained positive energy balance (as in overeating) has been postulated by Vidal-Puig to induce lipotoxic and inflammatory effects that may contribute to causing insulin resistance and its accompanying disease states.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.